Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

被引：0
|
作者：
Farastuk Bozorgmehr
Inn Chung
Petros Christopoulos
Johannes Krisam
Marc A. Schneider
Lena Brückner
Daniel Wilhelm Mueller
Michael Thomas
Stefan Rieken
机构：
[1] Thoraxklinik at University Hospital of Heidelberg,Department of Thoracic Oncology
[2] Member of the German Center for Lung Research DZL,Translational Lung Research Center Heidelberg TLRCH
[3] Institute of Medical Biometry and Informatics,Department of Radiation Oncology
[4] University Hospital of Heidelberg,undefined
[5] Thoraxklinik at University Hospital of Heidelberg,undefined
[6] Translational Research Unit (STF),undefined
[7] Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital,undefined
[8] University Medical Center Göttingen,undefined
来源：
BMC Cancer | / 20卷
关键词：
Non-small cell lung cancer; NSCLC; Radioimmunotherapy; Immune checkpoint inhibition; Anti-PD-L1 monoclonal antibody; Hypofractionated radiation; Geriatric risk profile;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 8 条
  • [1] Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
    Farastuk Bozorgmehr
    Inn Chung
    Petros Christopoulos
    Johannes Krisam
    Marc A. Schneider
    Lena Brückner
    Daniel Wilhelm Mueller
    Michael Thomas
    Stefan Rieken
    [J]. BMC Cancer, 23 (1)
  • [2] Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy-employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
    Bozorgmehr, Farastuk
    Chung, Inn
    Christopoulos, Petros
    Krisam, Johannes
    Schneider, Marc A.
    Brueckner, Lena
    Mueller, Daniel Wilhelm
    Thomas, Michael
    Rieken, Stefan
    [J]. BMC CANCER, 2020, 20 (01)
  • [3] Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy-The TRADE-hypo trial.
    Bozorgmehr, Farastuk
    Juergens, Jessica
    Hammer-Hellmig, Michaela
    Zum Bueschenfelde, Christian Meyer
    Classen, Johannes
    Alt, Juergen
    Stockinger, Marcus
    Ulmer, Matthias
    Mueller, Arndt-Christian
    Schuett, Philipp
    Eble, Michael J.
    Fischer, Juergen R.
    Lerchenmuller, Christian A.
    Overbeck, Tobias R.
    Pelz, Henning
    Schmidt, Bernd
    Wehler, Thomas
    Krisam, Johannes
    Thomas, Michael
    Rieken, Stefan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial (vol 20, 806, 2020)
    Bozorgmehr, Farastuk
    Chung, Inn
    Christopoulos, Petros
    Krisam, Johannes
    Schneider, Marc A.
    Brueckner, Lena
    Mueller, Daniel Wilhelm
    Thomas, Michael
    Rieken, Stefan
    [J]. BMC CANCER, 2023, 23 (01)
  • [5] Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial
    Bozorgmehr, F.
    Buchmeier, E. L.
    Hammer-Hellmig, M.
    Nestle, U.
    Zum Bueschenfelde, C. Meyer
    Weykamp, F.
    Classen, J.
    Schuett, P.
    Riedel, T.
    Wehler, T.
    Hey-Koch, S.
    Overbeck, T. R.
    Alt, J.
    Schmidberger, H.
    Behnisch, R.
    Chung, I.
    Thomas, M.
    Rieken, S.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S746 - S746
  • [6] DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy
    Filippi, A. R.
    Dziadziuszko, R.
    Garcia Campelo, M. R.
    Paoli, J-B.
    Sawyer, W.
    Perez, I. E. Diaz
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S747 - S747
  • [7] Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
    Filippi, A. R. R.
    Garcia-Campelo, M. R.
    Paoli, J. B.
    Kowalski, D.
    Bennati, C.
    Borghetti, P.
    Cortinovis, D. L.
    Delmonte, A.
    Genova, C.
    Van Hulst, S.
    Mroz, R.
    Nawrocki, S.
    Toledano, I.
    Tonini, G.
    Perez, I. Diaz
    Georgoulia, N. E.
    Foroutanpour, K.
    Dziadziuszko, R.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1302 - S1302
  • [8] Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
    Li, Juan
    Lu, Shun
    Tian, Yuke
    Jiang, Lan
    Li, Lu
    Xie, Shao-Hua
    Li, Qiang
    [J]. RADIOTHERAPY AND ONCOLOGY, 2024, 196
1